CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for...
Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA
13 Jun 2019
Maintenance pembrolizumab vs placebo for metastatic urothelial cancer
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
13 Jun 2019
NILE: Should we give everything to patients with unresectable locally advanced o...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
13 Jun 2019
SWOG 1314: A study of co-expression extrapolation (COXEN) with neoadjuvant chemo...
Prof Thomas Flaig - University of Colorado Denver, Denver, USA
10 Jun 2019
Genetic testing and PARP inhibitors in metastatic prostate cancer
Dr Neal Shore and Dr Joaquin Mateo
7 Jun 2019
Metastatic castration resistant prostate cancer: Updates from ASCO 2019
Dr Neal Shore, Dr Joaquin Mateo and Prof Karim Fizazi
7 Jun 2019
Prostate cancer updates: TITAN and ENZAMET
Prof Ian Davis and Prof Axel Merseburger
3 Jun 2019
Clinical updates for metastatic hormone sensitive prostate cancer at ASCO 2019
Prof Rob Jones, Prof Nick James, Prof Ian Davis, Prof Axel Merseburger
3 Jun 2019
Metastatic bladder cancer: Current practice and latest data from ASCO 2019
Dr Andrea Necchi, Dr Petros Grivas, Prof Arlene Siefker-Radtke, Prof Rob Jones
3 Jun 2019
Highlights from ASCO 2019
Asst. Prof Bishal Gyawali and Monique Biryiana
3 Jun 2019
Targeting agent enfortumab vedotin a novel treatment for patients with advanced ...
Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA
3 Jun 2019
New agent targeting Nectin-4 produces responses in nearly half of patients with ...
Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA
3 Jun 2019
